Zydus Cadila gets USFDA's nod to market Clobetasol ointment

Mumbai: Pharma Major, Zydus Cadila said that company has received the final approval from the US Food and Drug Administration (FDA) to market Clobetasol Propionate Ointment USP, 0.05%.

The drug is indicated to treat variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).

It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.